文献速递心律失常血脂与心血管预防

肿瘤患者接受延长QT间期药物时心电图监测不足

Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs.
PubMed 文献 · Heart · 2019-05-25

该研究基于加拿大安大略省人群数据库,纳入2005至2011年确诊的≥66岁肿瘤患者,评估接受QT延长药物者心电图监测的使用情况。结果显示48 236例患者中仅27%接受了心电图检查,且抗癌及止吐类QT延长药物反而与更少的心电图使用相关。

要点

  • 肿瘤患者中QT延长药物使用普遍,但心电图监测率仅27%。
  • 合并冠心病或心力衰竭者心电图使用较多,抗癌/止吐QT延长药反而更少。
  • 心电图廉价无创,应纳入常规毒性监测。

核心结论

  • 肿瘤患者中QT延长药物使用常见,但心电图监测明显不足。

研究设计与样本

  • 基于人群的回顾性队列研究,通过安大略癌症注册库链接多个行政数据库,纳入2005至2011年确诊的≥66岁肿瘤患者48 236例。

主要发现

  • 48 236例接受至少一种QT延长药物的患者中,仅27%进行了心电图检查。
  • 多变量分析中,近期癌症诊断(2005至2011年趋势p<0.001)、每增加一种QT延长药物(OR=1.15,95%CI 1.12至1.17)、合并冠心病(OR=1.31,95%CI 1.25至1.38)和心力衰竭(OR=1.25,95%CI 1.17至1.35)与更多心电图使用相关。
  • 使用抗癌QT延长药物(OR=0.74,95%CI 0.70至0.79)和止吐QT延长药物(OR=0.93,95%CI 0.88至0.99)反而与更少心电图使用相关。

临床怎么用

  • 对接受QT延长药物的肿瘤患者,应考虑将心电图纳入常规监测以评估毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We examined use of ECG monitoring in oncology patients prescribed QT-prolonging drugs. METHODS: Patients ≥66 years diagnosed with cancer between 2005 and 2011 were identified through the Ontario Cancer Registry and linked to multiple population-based administrative databases to ascertain demographics, comorbidities, prescription drug use, systemic therapy and ECG. QT-prolonging drugs were identified as per drug lists developed by the Arizona Center for Education and Research on Therapeutics. Univariable and multivariable analyses were used to examine factors associated with ECG use in patients on first-line systemic therapy. RESULTS: A total of 48 236 patients (median age 74; 49% women) received one or more drugs associated with a risk of QT-interval prolongation but only 27% of patients had an ECG performed. Factors associated with more ECG use on multivariable analysis included recent cancer diagnosis (p for trend <0.001 between 2005 and 2011), use of concurrent QT-prolonging drugs (OR=1.15 per each additional QT-prolonging drug, 95% CI 1.12 to 1.17) and the presence of coronary artery disease (OR 1.31; 95% CI 1.25 to 1.38) and heart failure (OR 1.25; 95% CI 1.17 to 1.35). Use of anticancer (OR 0.74; 95% CI 0.70 to 0.79) and antiemetic (OR 0.93; 95% CI 0.88 to 0.99) QT-prolonging drugs was paradoxically associated with less ECG use. CONCLUSIONS: Our study highlights common use of QT-prolonging drugs and underuse of ECG in oncology patients. Since ECG is an inexpensive, non-invasive and widely available test, it may be readily incorporated in the monitoring of patients for toxicities in routine clinical practice.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Pezo RC, Yan AT, Earle C, et al. Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs. Heart. 2019. PMID: 31129611. doi:10.1136/heartjnl-2018-314674

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。